The pharmaceutical industry has never been more exciting. At the dawn of this new decade, we are seeing incredible scientific breakthroughs in the industry. Gene therapy is becoming a reality, clinical diagnostics combined with treatments are paving the path for personalized medicine, and often under-represented diseases, like sickle cell disease and spinal muscular atrophy, are seeing not just one new treatment, but multiple life-changing solutions entering the market in 2019 and continuing in 2020. With all this change and excitement, there has been a whole lot of change within brand marketing organizations.
By Justin Freid, executive VP, growth and innovation, CMI/Compas. Have you ever tried to seesaw alone? Imagine the scene: a playground with two seesaws. On one sits a doctor. On the other one, a patient. The seesaw itself is your brand’s messaging – one seesaw has just HCP messaging and the other only DTC messaging. The […]
TBWA\WorldHealth Chief Strategy Officer Paul Pfleiderer, PhD, authored a white paper focused on the growing influence and importance of radio.
While pharma brands have made great strides in engaging with people on social media, Shuttlerock CEO Jonny Hendriksen has found that several myths have been perpetuated about translating existing video into shorter, mobile ads.
A look at potential new developments important to health communications and marketing.
Whatever the final outcome of pharma’s legal fight over HHS’ price transparency rule for DTC TV, the broader challenge of providing transparency to customers who are demanding it is not going away.
A federal judge struck down a new rule that would have forced pharma companies to include wholesale prices of drugs in TV ads.
U.S. drugmakers filed a lawsuit challenging a new government regulation that would require them to disclose the list price of prescription drugs in direct-to-consumer television advertisements.
HHS announced its new price transparency rules for direct-to-consumer TV ads. Now the industry has to sort out what to do about them.
We are on the verge of a medical renaissance, a period of accelerated progress in the treatment and management of rare diseases. This reawakening also brings with it challenges that we must grapple with.